Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Dec 2024 value amounting to -$5.29.

  • Phathom Pharmaceuticals' EPS (Weighted Average and Diluted) rose 68.94% to -$0.41 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.77, marking a year-over-year increase of 34.43%. This contributed to the annual value of -$5.29 for FY2024, which is 34.61% down from last year.
  • According to the latest figures from FY2024, Phathom Pharmaceuticals' EPS (Weighted Average and Diluted) is -$5.29, which was down 34.61% from -$3.93 recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of -$3.89 in FY2021 and a low of -$5.29 during FY2024.
  • For the 3-year period, Phathom Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$4.76, with its median value being -$5.05 (2022).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first grew by 22.18% in 2023, then slumped by 34.61% in 2024.
  • Phathom Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$3.89 in 2021, then fell by 29.82% to -$5.05 in 2022, then climbed by 22.18% to -$3.93 in 2023, then tumbled by 34.61% to -$5.29 in 2024.